NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD
Cardiff Oncology, Inc. (CRDF) has a consensus analyst rating of Buy, based on 12 analysts covering the stock. Of those, 8 recommend buying, 3 recommend holding, and 1 recommend selling.
No price target data available.
Be the first to know when stocks drop below their intrinsic value.
